/DGX
DGX Stock - Quest Diagnostics Incorporated
Healthcare|Medical - Diagnostics & ResearchNYSE
$176.06-0.05%
$0.09 (-0.05%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.43
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).78
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+14.0%upside
Target: $200.71
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DGX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$174.30 – $177.82
TARGET (TP)$200.64
STOP LOSS$161.98
RISK/REWARD1:1.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.62
52W High$197.55
52W Low$148.70
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B |
| Gross Profit | $3.24B | $3.07B | $3.43B | $4.21B | $3.63B |
| Gross Margin | 32.9% | 33.2% | 34.7% | 39.0% | 38.5% |
| Operating Income | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B |
| Net Income | $871.00M | $854.00M | $946.00M | $2.00B | $1.43B |
| Net Margin | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% |
| EPS | $7.80 | $7.59 | $8.12 | $15.90 | $10.68 |
Company Overview
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
47%
Hold / Neutral
7
47%
Sell / Underperform
1
7%
Analyst Consensus🔴 Bearish
7 Bullish8 Neutral/Bearish
Price Targets
$163
Average Target
↓ 7.6% Downside
Now
$125
Low
$163
Average
$195
High
Based on 18 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 25th 2025 | Robert W. Baird | Downgrade | Neutral | $194 |
| April 2nd 2025 | Redburn Atlantic | Initiation | Buy | $195 |
| March 4th 2025 | Citigroup | Downgrade | Neutral | $185 |
| January 6th 2025 | Leerink Partners | Upgrade | Outperform | $174← $169 |
| December 17th 2024 | Morgan Stanley | Upgrade | Overweight | $172← $145 |
| December 10th 2024 | Jefferies | Resumed | Buy | $185← $175 |
| October 23rd 2024 | Robert W. Baird | Upgrade | Outperform | $182← $157 |
| August 28th 2024 | Evercore ISI | Resumed | In-line | $165 |
| July 10th 2024 | Citigroup | Upgrade | Buy | $165← $145 |
| February 26th 2024 | Leerink Partners | Initiation | Market Perform | $135 |
| February 7th 2024 | Jefferies | Upgrade | Buy | $155← $140 |
| January 3rd 2024 | Barclays | Initiation | Equal Weight | $145 |
| December 12th 2023 | BofA Securities | Upgrade | Buy | $160← $140 |
| June 29th 2023 | Piper Sandler | Initiation | Neutral | - |
| May 2nd 2023 | BofA Securities | Downgrade | Neutral | $148← $166 |
Earnings History & Surprises
DGXBeat Rate
100%
Last 18 quarters
Avg Surprise
+5.9%
EPS vs Estimate
Beats / Misses
18/0
Last 12 quarters
Latest EPS
$2.60
Q4 2025
EPS Surprise History
Q1 24
+1.9%
$2.15vs$2.11
Q2 24
+9.7%
$2.04vs$1.86
Q3 24
+0.4%
$2.35vs$2.34
Q4 24
+1.8%
$2.30vs$2.26
Q1 25
+1.8%
$2.23vs$2.19
Q2 25
+2.8%
$2.21vs$2.15
Q3 25
+1.9%
$2.62vs$2.57
Q4 25
+3.6%
$2.60vs$2.51
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 20, 2026 | — | — | — | — |
Q1 2026 | Jan 29, 2026 | $2.36 | — | — | — |
Q4 2025 | Oct 21, 2025 | $2.51 | $2.60 | +3.6% | ✓ BEAT |
Q3 2025 | Jul 22, 2025 | $2.57 | $2.62 | +1.9% | ✓ BEAT |
Q2 2025 | Apr 22, 2025 | $2.15 | $2.21 | +2.8% | ✓ BEAT |
Q1 2025 | Jan 30, 2025 | $2.19 | $2.23 | +1.8% | ✓ BEAT |
Q4 2024 | Oct 22, 2024 | $2.26 | $2.30 | +1.8% | ✓ BEAT |
Q3 2024 | Jul 23, 2024 | $2.34 | $2.35 | +0.4% | ✓ BEAT |
Q2 2024 | Apr 23, 2024 | $1.86 | $2.04 | +9.7% | ✓ BEAT |
Q1 2024 | Feb 1, 2024 | $2.11 | $2.15 | +1.9% | ✓ BEAT |
Q4 2023 | Oct 24, 2023 | $2.19 | $2.22 | +1.4% | ✓ BEAT |
Q3 2023 | Jul 26, 2023 | $2.27 | $2.30 | +1.3% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $1.97 | $2.04 | +3.6% | ✓ BEAT |
Q1 2023 | Feb 2, 2023 | $1.90 | $1.98 | +4.2% | ✓ BEAT |
Q4 2022 | Oct 20, 2022 | $2.19 | $2.36 | +7.8% | ✓ BEAT |
Q3 2022 | Jul 21, 2022 | $2.29 | $2.36 | +3.1% | ✓ BEAT |
Q2 2022 | Apr 21, 2022 | $2.97 | $3.22 | +8.4% | ✓ BEAT |
Q1 2022 | Feb 3, 2022 | $3.18 | $3.33 | +4.7% | ✓ BEAT |
Q4 2021 | Oct 21, 2021 | $2.88 | $3.96 | +37.5% | ✓ BEAT |
Q3 2021 | Jul 22, 2021 | $2.87 | $3.18 | +10.8% | ✓ BEAT |
Latest News
Octave Bioscience Enters Strategic Collaboration With Quest Diagnostics To Make The Octave MS Disease Activity Test Widely Accessible Through Quest's Nationwide Specimen-Collection Network
📈 PositiveBenzinga•Dec 1, 2025, 01:37 PM
Quest Diagnostics' New Blood Tests Accurately Detect Alzheimer's, Study Finds
📈 PositiveBenzinga•Oct 27, 2025, 11:47 AM
Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $195
➖ NeutralBenzinga•Oct 22, 2025, 04:58 PM•Also:
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $205
➖ NeutralBenzinga•Oct 22, 2025, 02:19 PM
Leerink Partners Maintains Outperform on Quest Diagnostics, Raises Price Target to $210
📈 PositiveBenzinga•Oct 21, 2025, 08:56 PM
Quest Diagnostics shares are trading lower after the company reported Q3 financial results and lowered ita FY25 GAAP EPS guidance below estimates.
📉 NegativeBenzinga•Oct 21, 2025, 02:35 PM
Quest Diagnostics Q3 Adj. EPS $2.60 Beats $2.50 Estimate, Sales $2.816B Beat $2.736B Estimate
📈 PositiveBenzinga•Oct 21, 2025, 10:48 AM
Quest Diagnostics Lowers FY2025 GAAP EPS Guidance from $8.60-$8.80 to $8.58-$8.66 vs $8.68 Est
📉 NegativeBenzinga•Oct 21, 2025, 10:47 AM
Quest Diagnostics Raises FY2025 Adj EPS Guidance from $9.63-$9.83 to $9.76-$9.84 vs $9.75 Est; Raises FY2025 Sales Guidance from $10.800B-$10.920B to $10.960B-$11.000B vs $10.865B Est
📈 PositiveBenzinga•Oct 21, 2025, 10:47 AM
UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $190
➖ NeutralBenzinga•Oct 17, 2025, 01:52 PM
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $210
📈 PositiveBenzinga•Oct 17, 2025, 01:26 PM
NVIDIA Posts On X "Today is the day. NVIDIA DGX Sparks are now shipping from us and from our partners.
📈 PositiveBenzinga•Oct 15, 2025, 06:15 PM•Also:
Reported Earlier, NVIDIA Unveils DGX Spark, World's Smallest AI Supercomputer Delivering 1 Petaflop Performance And 128GB Unified Memory For Developers
📈 PositiveBenzinga•Oct 14, 2025, 05:04 AM•Also:
Evercore ISI Group Maintains In-Line on Quest Diagnostics, Raises Price Target to $190
📈 PositiveBenzinga•Oct 8, 2025, 01:09 PM
Guardant Health And Quest Diagnostics Collaborate To Make Guardant's Shield Blood-Based Screening Test Available To Physicians And Patients Served By Quest In US
📈 PositiveBenzinga•Sep 24, 2025, 12:19 PM•Also:
Quest Diagnostics Expands Epic Integration With Aura Beaker MyChart And Billing Systems To Streamline National Laboratory Operations
📈 PositiveBenzinga•Sep 23, 2025, 11:10 AM
Cadence Expands Cadence Reality Digital Twin Platform Library With Digital Twin Of NVIDIA DGX SuperPOD With DGX GB200 Systems
📈 PositiveBenzinga•Sep 9, 2025, 01:04 PM•Also:
Quest Diagnostics Announces Advanced Pharmacogenomic Laboratory Test Service To Guide Drug Therapy Based On Genetic Response
📈 PositiveBenzinga•Sep 4, 2025, 01:36 PM
Corewell Health And Quest Diagnostics Form Joint Venture To Build Advanced Michigan Lab And Manage 21 Hospital Labs Statewide
📈 PositiveBenzinga•Aug 26, 2025, 01:13 PM
Baird Downgrades Quest Diagnostics to Neutral, Maintains Price Target to $194
➖ NeutralBenzinga•Aug 25, 2025, 02:22 PM
Frequently Asked Questions about DGX
What is DGX's current stock price?
Quest Diagnostics Incorporated (DGX) is currently trading at $176.06 per share. The stock has moved -0.05% today.
What is the analyst price target for DGX?
The average analyst price target for DGX is $200.64, based on 1 analyst.
What sector is Quest Diagnostics Incorporated in?
Quest Diagnostics Incorporated operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NYSE exchange.
What is DGX's market cap?
Quest Diagnostics Incorporated has a market capitalization of $19.67 billion, making it a large-cap company.
Does DGX pay dividends?
No, Quest Diagnostics Incorporated does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorICLR
ICON Public Limited Company
$173.77
Mkt Cap: $13.3B
ILMN
Illumina, Inc.
$134.78
Mkt Cap: $20.6B
INCY
Incyte Corporation
$102.69
Mkt Cap: $20.2B
LH
Labcorp Holdings Inc.
$252.03
Mkt Cap: $20.9B
MEDP
Medpace Holdings, Inc.
$568.36
Mkt Cap: $16.0B
THC
Tenet Healthcare Corporation
$196.33
Mkt Cap: $17.3B
UTHR
United Therapeutics Corporation
$517.13
Mkt Cap: $23.1B
WAT
Waters Corporation
$378.03
Mkt Cap: $22.5B
WST
West Pharmaceutical Services, Inc.
$272.54
Mkt Cap: $19.6B
ZBH
Zimmer Biomet Holdings, Inc.
$89.13
Mkt Cap: $17.7B
Explore stocks similar to DGX for comparison